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The Foundation Fighting Blindness, a 501(c)(3) nonprofit organization, established an
international consortiumof inherited retinal disease specialists in 2016,with amission to
accelerate the development of treatments for rare, inherited retinal degenerations, such
as retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis, Usher syndrome,
choroideremia, and achromatopsia. The Consortium accomplishes its mission by evalu-
ating novel outcomemeasures, sharing standardized study protocols and datasets, and
disseminating findings. Having established research infrastructure in the first 3 years,
including 39 global research sites, the network is nowpoised to expand its infrastructure
for trials of new therapies in partnershipwith industry. Thismodel represents an innova-
tive approach to overcome challenges of therapeutic development for rare diseases.
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Introduction
Recently, in response to a Request for Informa-
tion from the US Food and Drug Administration, we
shared our experience building a rare disease clinical
trial network (https://beta.regulations.gov/document/
FDA-2020-N-0837-0027). We thought the readers of
TVST would be interested in how a rare disease
clinical trial network can bring together clinical
experts and inform industry partners to address the
challenges encountered when developing therapies for
rare diseases.
The Foundation Fighting Blindness (the Founda-
tion) is a 501(c)(3) nonprofit organization established
in 1971 with a mission to accelerate the develop-
ment of treatments and cures for inherited retinal
degenerations (IRDs), including retinitis pigmentosa,
Stargardt disease, Leber congenital amaurosis, Usher
syndrome, choroideremia, achromatopsia, and others.
These conditions are associated with a significant
economic burden owing to decreased workforce partic-
ipation and loss of well-being.1 As a group, these rare
IRDs affect approximately 4.5 to 6.8 million people
worldwide and 200,000 to 300,000 Americans. Thus,
each of the rare IRDs meets the US Food and Drug
Administration’s definition of an orphan disease. The
term “rare IRD” is a convenient, but misleading,
label to describe a collection of heterogenous diseases.
They are genetically diverse (>270 causative genes have
been identified to date) and have vastly different clini-
cal manifestations in terms of age of onset, sever-
ity of disease, rate of progression, and patterns of
anatomic and functional abnormalities. Understand-
ing this phenotypic heterogeneity poses an important
challenge for therapy developers. To be successful, they
must identify suitable outcome measures and match
themwith their therapeutic strategy (including delivery
to the appropriate retinal cell types) and the therapeutic
goal (e.g., slowing progression or improving vision).2
The variety of promising treatment approaches is
evident in the current therapeutic pipeline, ranging
broadly from gene editing and augmentation for early
stage disease; to neuroprotection for midstage disease;
and to prosthetics, optogenetics, and cell therapy to
restore some light sensation in late-stage disease.3,4
The Foundation’s program of sponsored clinical
studies began in 2010. It has led to the development
of novel outcome measures and added greatly to our
understanding of IRDs. The first study, a random-
ized clinical trial of valproic acid (NCT01233609) in
individuals with autosomal dominant retinitis pigmen-
tosa failed to demonstrate a treatment benefit, but
was the basis for research that identified the area of
the ellipsoid zone (intact photoreceptors), estimated
from optical coherence tomography, as a sensitive
and reliable outcome measure in retinitis pigmen-
tosa.5,6 Numerous outcome measures in Stargardt
disease have been characterized from our second study,
ProgStar (NCT01977846).7–10 The scientific output
from this study, in the form of 22 publications and
numerous downloads of study datasets, has generated
significant industry interest and pointed the way to
our most recent framework for collaborative clinical
research.
To extend the success of our early clinical studies,
the Foundation established an international consor-
tium of IRD specialists in 2016 (https://public.jaeb.org/
ffb), whose mission is to accelerate the development
of treatments for IRDs. The Consortium is develop-
ing centers of excellence to participate in sponsored
clinical studies that generate robust and high-quality
data using standardized protocols.4 Investigators from
participating clinical centers collaborate to assess risk
factors and develop outcome variables from prospec-
tive natural history studies of IRDs, using standard-
ized protocols. Using this information, the Consor-
tium focuses on clinical trial development, including
the development of hypotheses, creating study proto-
cols, carrying out clinical trials, analyzing the data and
publishing the results. As part of the Consortium’s
mission to stimulate further hypothesis generation and
innovation, de-identified datasets will be archived in a
central repository after study completion, and readily
available to other researchers via a data transfer and
processing agreement. Currently, the Consortium has
39 sites (28 in the United States) in 11 countries across
North America, South America, Western Europe, and
the Middle East. In addition to the sites, the research
infrastructure includes a coordinating center, reading
centers, technical experts, and oversight committees.
All of these components have been developed through
our experience launching 2 large multicenter natural
history studies, Rate of Progression inUSH2A–related
Retinal Degeneration (RUSH2A; NCT03146078) and
Rate of Progression in EYS-related Retinal Degenera-
tion (Pro-EYS; NCT04127006).
Recruitment for RUSH2A and Pro-EYS has been
aided by the Foundation’s My Retina Tracker Registry
and its associated genetic testing program.11 The
registry is open to individuals with IRDs (or their
caregivers) who complete survey modules that cover
their diagnosis, family history, diagnostic journey,
current vision, and overall health. This information,
in conjunction with genetic test results, enables the
Foundation’s registry staff to identify and contact
registry members who may be candidates for clinical
studies.
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Now in our fourth year and with critical infrastruc-
ture in place to support treatment trials, the Consor-
tium has begun to focus on three inter-dependent
objectives. First, we aim to ensure we are produc-
tive and impactful by soliciting research ideas from
our investigators and others, prioritizing work to
develop novel outcome measures, and disseminating
our findings. Second, we are focused on improving cost,
efficiency, and quality because we have an obligation
to donors who fund our work and because economics
play a large role in determining whether sites can
participate in research studies. Third, we are build-
ing avenues toward sustainability, which we view in
terms of investigator engagement and project cofund-
ing. We envision mutually beneficial partnerships of
many forms, including early access to study datasets,
joint development of novel outcome measures, and
leveraging our entire research infrastructure to conduct
clinical trials of novel treatments. Whatever form our
partnerships take, the Consortium will remain open
and flexible to conduct clinical trials of promising new
therapies, even if they have not yet attracted industry
funding.
We have evolved over time in response to numer-
ous challenges related to economics (e.g., ensuring site
budgets are at least cost-neutral), site participation and
engagement, coordination of international sites (such
as translation of patient documents), the needs of
industry partners (e.g., early access to data, concerns
with study timelines), and novel coronavirus disease
2019 research disruptions. Although these challenges
have been significant, we are frequently reminded of
another inherent challenge that rare disease networks
need to address. Many rare diseases do not have well-
established clinical outcome measures,4 and, as in our
case, it is an explicit goal of the network to develop
relevant outcome measures, including patient-reported
outcomes or performance-based tests to assess disease
impacts. However, these innovations require signifi-
cant investment in standardizing protocols suitable for
multicenter studies, developing training and certifica-
tion processes, aligning investigators as to the impor-
tance of the resource-intensive work, strategic partner-
ingwith industry, and feedback frompatients.We strive
to not only collect data from patients in an efficient
manner, but also to explore optimal methods to analyze
the data.
We believe these efforts will pay tremendous
dividends. Careful follow-up of well-characterized
cohorts with rare diseases fills knowledge gaps about
anatomy, function, social determinants of health, and
disease impacts. These data can be useful to identify
individuals who are most likely to benefit from a
new therapy and, therefore, facilitate the design and
enrollment of clinical trials. The eventual success of
new therapies in clinical trials also depends on having
valid and reliable outcome measures. These tools are
being developed by the scientific and clinical experts
in our network and shared with the greater research
community, thus removing development uncertainty
and paving the way for the accelerated development of
valuable new therapies.
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